China Pharma Announces Pricing of $5 Million Registered Direct Offering

China Pharma Holdings, Inc. (NYSE American: CPHI), a fully-integrated specialty pharmaceuticals company based in Haikou, China, has announced the pricing of its registered direct offering of 2.5 million shares of common stock at a purchase price of $2 per share. The transaction, which aims to raise gross proceeds of $5 million, is expected to close on or about July 23, 2026. FT Global Capital, Inc. is serving as the exclusive placement agent for this offering.

The proceeds from this offering are intended for working capital and general corporate purposes, which may include funding ongoing operational activities and supporting future growth initiatives. China Pharma Holdings specializes in developing, manufacturing, and marketing a diversified portfolio of pharmaceutical products, particularly targeting conditions with high incidence and mortality rates in China, such as cardiovascular, central nervous system, infectious, and digestive diseases. The company operates under a cost-effective, high-margin business model and boasts a scalable production capacity through eight GMP-certified product lines.

In the context of the pharmaceutical industry in China, the demand for specialty pharmaceuticals continues to rise, driven by an aging population and increasing healthcare needs. China Pharma's strategic focus on high-demand therapeutic areas positions it well to capitalize on these trends. The company’s broad distribution network across major cities and provinces further enhances its ability to reach a wide customer base, which is crucial in a competitive market landscape.

The offering comes at a time when many companies in the pharmaceutical sector are seeking to strengthen their balance sheets and enhance liquidity in response to ongoing market volatility and economic uncertainties. By securing additional capital, China Pharma Holdings aims to bolster its operational capabilities and maintain its competitive edge in the rapidly evolving pharmaceutical market.

Overall, this fundraising initiative reflects a broader trend in the pharmaceutical industry where companies are increasingly turning to capital markets to support growth and innovation. As the sector continues to adapt to changing regulatory environments and market dynamics, strategic capital raises will likely remain a critical component for companies looking to navigate the complexities of the healthcare landscape in China and beyond.